Cargando…

Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial

INTRODUCTION: In the IMPACT trial, single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) reduced moderate/severe exacerbation rates versus FF/VI or UMEC/VI dual therapy in patients with chronic obstructive pulmonary disease (COPD); however, pneumonia incidence was hi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Halpin, David M. G., Criner, Gerard J., Dransfield, Mark T., Han, MeiLan K., Hartley, Benjamin, Harvey, Catherine, Jones, C. Elaine, Kato, Motokazu, Lange, Peter, Lettis, Sally, Lomas, David A., Martinez, Fernando J., Martin, Neil, Singh, Dave, Wise, Robert, Zheng, Jinping, Lipson, David A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137798/ https://www.ncbi.nlm.nih.gov/pubmed/33201438 http://dx.doi.org/10.1007/s41030-020-00136-3

Ejemplares similares

Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT
por: Dransfield, Mark T., et al.
Publicado: (2021)

The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial
por: Han, MeiLan K., et al.
Publicado: (2020)

Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study
por: Tabberer, Maggie, et al.
Publicado: (2020)

InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations
por: Singh, Dave, et al.
Publicado: (2021)

Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis
por: Han, MeiLan K., et al.
Publicado: (2021)

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
por: Day, Nicola C., et al.
Publicado: (2020)

The effect of exacerbation history on outcomes in the IMPACT trial
por: Halpin, David M.G., et al.
Publicado: (2020)

Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease
por: Lipson, David A., et al.
Publicado: (2020)

Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses
por: Halpin, David M.G., et al.
Publicado: (2018)

Time‐Dependent Risk of Cardiovascular Events Following an Exacerbation in Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analysis From the IMPACT Trial
por: Dransfield, Mark T., et al.
Publicado: (2022)

Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial
por: Ismaila, Afisi S, et al.
Publicado: (2019)

Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trial
por: Thompson, Philip J., et al.
Publicado: (2022)

Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial
por: Gabrio, Andrea, et al.
Publicado: (2022)

Discordant diagnostic criteria for pneumonia in COPD trials: a review
por: Wise, Robert A., et al.
Publicado: (2021)

Reply to López-Campos et al.: Triple-Therapy Trials for Chronic Obstructive Pulmonary Disease: Methodological Considerations in the Mortality Effect
por: Lipson, David A., et al.
Publicado: (2021)

The IMPACT Study – Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population
por: Kato, Motokazu, et al.
Publicado: (2019)

Measuring disease activity in COPD: is clinically important deterioration the answer?
por: Singh, Dave, et al.
Publicado: (2020)

Correction to: Measuring disease activity in COPD: is clinically important deterioration the answer?
por: Singh, Dave, et al.
Publicado: (2021)

Preventing clinically important deterioration with single-inhaler triple therapy in COPD
por: Naya, Ian, et al.
Publicado: (2018)

Reply to Suissa: Mortality in IMPACT: Confounded by Asthma?
por: Lipson, David A., et al.
Publicado: (2020)

One More Time: The Impact of Inhaled Corticosteroid Withdrawal on IMPACT
por: Han, MeiLan K., et al.
Publicado: (2020)

Reply to Wang and Lai: The Role of Eosinophils during the Withdrawal of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease
por: Han, MeiLan K., et al.
Publicado: (2021)

Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life
por: Tabberer, Maggie, et al.
Publicado: (2018)

Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease
por: Halpin, David M. G., et al.
Publicado: (2021)

Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD
por: Bourbeau, Jean, et al.
Publicado: (2021)

Efficacy and Safety of Once-Daily Inhaled Umeclidinium in Asian Patients with COPD: Results from a Randomized, Placebo-Controlled Study
por: Zhong, Nanshan, et al.
Publicado: (2020)

From GOLD 0 to Pre-COPD
por: Han, MeiLan K., et al.
Publicado: (2021)

Reply to Thomson, to Neder et al., and to Wouters
por: Han, MeiLan K., et al.
Publicado: (2021)

Risk factors for exacerbations and pneumonia in patients with chronic obstructive pulmonary disease: a pooled analysis
por: Hartley, Benjamin F., et al.
Publicado: (2020)

Comparative effectiveness of triple therapy versus dual bronchodilation in COPD
por: Voorham, Jaco, et al.
Publicado: (2019)

When is dual bronchodilation indicated in COPD?
por: Thomas, Mike, et al.
Publicado: (2017)

A Response to: Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis”
por: Ismaila, Afisi S., et al.
Publicado: (2023)

The Role of Tiotropium+Olodaterol Dual Bronchodilator Therapy in the Management of Chronic Obstructive Pulmonary Disease
por: Halpin, David M. G.
Publicado: (2018)

INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice
por: Halpin, David M.G., et al.
Publicado: (2021)

PROMETHEUS: Long-Term Exacerbation and Mortality Benefits of Implementing Single-Inhaler Triple Therapy in the US COPD Population
por: Criner, Gerard, et al.
Publicado: (2023)

Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial
por: Zheng, Jinping, et al.
Publicado: (2021)

Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD – mixed treatment comparisons of clinical efficacy
por: Stynes, Gillian, et al.
Publicado: (2015)

Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis
por: Ismaila, Afisi S., et al.
Publicado: (2022)

Inhaled corticosteroids and COVID-19-related mortality: confounding or clarifying?
por: Singh, Dave, et al.
Publicado: (2020)

Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial
por: Rabe, Klaus F., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jep5rdo377msmibmlvvii5lj9k